<DOC>
	<DOCNO>NCT01568203</DOCNO>
	<brief_summary>The purpose study assess safety tolerability AMG 579 follow single oral dose administration healthy subject ( Part A ) patient schizophrenia stable schizoaffective disorder ( Part B ) . The study healthy subject ( Part A ) conclude , follow protocol amendment , enrol patient schizophrenia stable schizoaffective disorder ( Part B ) .</brief_summary>
	<brief_title>First-in-Human Study Evaluate AMG 579 Healthy Subjects Patients With Stable Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Diagnosis schizophrenia ( chronic , type ) schizoaffective disorder accord Diagnostic Statistical Manual Mental Disorders , 4th edition Text Revision ( DSMIVTR ) criteria Mini International Neuropsychiatric Interview ( M.I.N.I . ) 6.0 Schizophrenia Psychotic Disorders Studies Body weight great equal 50 kg body mass index ( BMI ) 18 38.0 kg/m2 , inclusive , screen Patient judge Investigator likely tolerate antipsychotic medication duration trial ( patient withdraw currently take antipsychotic medication ) Clinically stable , judged investigator , nonacute phase least 12 week within enrollment . If patient antipsychotic medication , must second generation oral antipsychotic therapy ( eg , ziprasidone , quetiapine , olanzapine , etc ) least 8 week within enrollment least one month within enrollment stable dose Hospitalized psychiatric symptom 3 month within enrollment Patients evidence mental retardation history clinical examination know premorbid IQ â‰¤ 70 Current risk selfharm violence determine investigator , current risk suicide history suicidal behavior within 12 month enrollment , and/or ongoing suicidal ideation assess use ColumbiaSuicidal Severity Rating Scale ( CSSRS ) screening ( eg , response `` yes '' Suicidal Ideation question CSSRS past 12 month ) . Additional critera apply . Eligibility criteria healthy subject ( Part A ) outline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>single dose , safety , healthy subject , schizoaffective disorder , AMG 579</keyword>
</DOC>